ZLAB•benzinga•June 2, 2025 at 11:11 AM

Zai Lab Limited Announced That Updated Data From An Ongoing, Global Phase 1A/1B Clinical Trial (NCT06179069) Evaluating Zocilurtatug Pelitecan, Or Zl-1310, The Company's Potential First-in-class, Delta-like Ligand (DLL3) Antibody-drug Conjugate (ADC) For

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 2, 2025 by benzinga